The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

The most well-known is CRISPR-Cas9, adapted for human use as the first FDA-approved genetic editing technique. In the past year, researchers at Rockefeller's Laboratory of Bacteriology ...

An infant in Philadelphia has been successfully treated with a customized Crispr gene-editing therapy for a rare and deadly disease, doctors reported Thursday—a breakthrough in the futuristic ...

An infant with a rare urea cycle disorder became the first patient to receive a personalized gene-editing therapy. His care team developed the one-of-a-kind medication in just 6 months.

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell ... access scheme and with a confidential discount. The CRISPR-based therapy will be an option for SCD patients ...

Scientific interest in CRISPR has soared over the last decade as an opportunity to systematically engineer therapies for hard-to-treat diseases, from rare genetic disorders to common chronic ...

These markers showed high sensitivity and specificity in detecting cyst-bearing mice and had a positivity rate of 30% in humans with prior immunity. Bradyzoite serology helps to discriminate between ...

As of 10:04:27 am GMT-4. Market open.